Exploring the targets and molecular mechanism of glycyrrhetinic acid against diabetic nephropathy based on network pharmacology and molecular docking

doi:10.4239/wjd.v14.i11.1672

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2187)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-8) series, Tables (1-2) series.

Item

Count

PDF

WORD

HTML

1306

Figures (1-8)

140

Tables (1-2)

200

Sum=1717

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

259

Sum=358

Nov 15, 2023 (publication date) through Jul 22, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Diabetes. Nov 15, 2023; 14(11): 1672-1692
Published online Nov 15, 2023. doi: 10.4239/wjd.v14.i11.1672

Table 1 Drugs and reagents

Reagent	Manufacturer	Article number
DMEM high sugar medium	Gibco Corporation, United States	11960044
Fetal bovine serum	Corning Corporation, United States	35-081-CV
Phosphate buffer	Beijing Soleibao Company	SH30256.01
0.25% trypsin protein	Gibco Corporation, United States	T1320
Green streptomycin mixture	Beijing Soleibao Company	P1400-100
CCK-8 kit	Jiangsu Kaiji Biology	KGA317
Cell cycle kit	Jiangsu Kaiji Biology	KGA512
Apoptosis kit	Jiangsu Kaiji Biology	KGA101
BCA protein content detection kit	Jiangsu Kaiji Biology	KGP902
Total protein extraction kit	Jiangsu Kaiji Biology	KGP250
5× loading buffer	Jiangsu Kaiji Biology	KGP101
Chemiluminescence kit	Jiangsu Kaiji Biology	KGS133
10× WB washing solution	Jiangsu Kaiji Biology	KGP109
PVDF membrane	Millipore Corporation	IPVH00010
10× electrotransfer buffer	Jiangsu Kaiji Biology	KGP102
0.25% trypsin protein (EDTA not included)	Gibco Corporation	T1320
PI3K rabbit antibody	Abcam	ab302958
p-PI3K rabbit antibody	Abcam	ab278545
AKT rabbit antibody	Abcam	ab283852
Rabbit antibody to p-AKT	Abcam	ab38449
INSR Rabbit antibody	Wuhan Sanying	20433-1-AP
Rabbit antibody to GSK3	Wuhan Sanying	13419-1-AP
Rabbit IgG	Santa Cruzgong Company, United States	sc2004
GAPDH	Abcam	Ab8245

Table 2 Drug active ingredient

ID	Phytochemical name	OB (%)	DL
MOL005002	Beta-glycyrrhetinic acid	17.41	0.74
MOL004804	Alpha-glycyrrhetinic acid	22.05	0.74

OB: Oral bioavailability; DL: Drug-likeness.

Citation: Meng FD, Yuan L, Xu DJ, Che MY, Hou SZ, Lu DD, Liu WJ, Nan Y. Exploring the targets and molecular mechanism of glycyrrhetinic acid against diabetic nephropathy based on network pharmacology and molecular docking. World J Diabetes 2023; 14(11): 1672-1692
URL: https://www.wjgnet.com/1948-9358/full/v14/i11/1672.htm
DOI: https://dx.doi.org/10.4239/wjd.v14.i11.1672